IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

This study tests combining irreversible electroporation (IRE) — a non-thermal procedure that destroys tumor cells using electrical pulses — with a dual-function antibody that blocks two immune checkpoints (PD-1 and CTLA-4) in people with locally advanced pancreatic cancer that has not responded to standard chemotherapy. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of locally advanced pancreatic cancer - Your cancer has failed standard first-line chemotherapy (called AG therapy — gemcitabine plus nab-paclitaxel) - You have adequate organ function and performance status (able to carry out daily activities) **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have not yet tried standard chemotherapy - Your overall health or organ function does not meet minimum requirements Talk to your doctor to see if this trial is right for you.